WHO WE ARE Intra-ImmuSG Pte Ltd (IISG) is a Phase 2 clinical-stage biotechnology company

PRL3 is an intracellular protein (inside cell) overexpressed in many tumors and has been reported globally by many research laboratories. Since PRL3 is specifically overexpressed in tumors but undetectable in most normal tissues, we anticipate that PRL3 is an excellent tumor specific antigen for cancer therapy. Traditionally, intracellular oncoproteins (such as PRL3) are targeted by small chemical inhibitors (chemotherapy), mainly because intracellular compartments are presumed to be inaccessible to large antibody drugs. However, as compared to chemotherapy, antibody therapy is more target-specific and has less off-target side effects.

In 2016, PRL3-zumab was approved for Phase I clinical trial by Health Sciences Authority (HSA), Singapore. After the successful safety trial, Phase II clinical trial for drug efficacy was approved by HSA in 2019.

In 2020, Phase II clinical trials have been approved by the Food and Drug Administration (FDA) in the United States and by the National Medical Products Administration (NMPA) in China to conduct multi-center clinical trials in USA and China respectively.

IISG is spearheading a new era of Cancer Immunotherapy that specifically targets tumors, yet keeping normal organs unharmed, thus greatly reducing side-effects. Today, IISG has developed a strong portfolio of next-generation antibody therapies to treat a spectrum of cancer indications via targeting multiple intracellular oncoproteins.